Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 13/20 | 0.82 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.82 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2212471 | 0.90 | KCNA5 (1.00) | KCNA5KCNA3KCNK3TAS1R3TAS1R1 | |
| SCHEMBL498107 | 0.90 | KCNA5 (1.00) | KCNA5KCNA3KCNK3TAS1R3TAS1R1 | |
| SCHEMBL498106 | 0.90 | KCNA5 (1.00) | KCNA5KCNA3KCNK3TAS1R3TAS1R1 | |
| SCHEMBL727201 | 0.85 | KCNA5 (0.76) | KCNA5KCNA3KCNK3TAS1R3TAS1R1 | |
| SCHEMBL5697890 | 0.85 | KCNA5 (0.76) | KCNA5KCNA3KCNK3TAS1R3TAS1R1 | |
| SCHEMBL12434426 | 0.84 | KCNA5 (0.88) | KCNA5KCNA3KCNK3TAS1R3TAS1R1 | |
| SCHEMBL12434428 | 0.84 | KCNA5 (0.88) | KCNA5KCNA3KCNK3TAS1R3TAS1R1 | |
| SCHEMBL12434425 | 0.84 | KCNA5 (0.88) | KCNA5KCNA3KCNK3TAS1R3TAS1R1 | |
| SCHEMBL4230136 | 0.83 | KCNA5 (0.58) | KCNA5KCNA3KCNK3TAS1R3TAS1R1 | |
| SCHEMBL13801064 | 0.83 | KCNA5 (1.00) | KCNA5KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| WO-2007124849-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | KCNN3, CACNA1I, KCNN1 | KCNA5 67/4885KCNA3 28/4885KCNK3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.